Brought to you by 
Novartis makes $84mm JE vaccine deal with Intercell; terminated
23 Jun 2015
Executive Summary
Intercell (vaccines) has granted Novartis marketing and distribution rights to its Phase III second-generation IC51 vaccine for Japanese Encephalitis (JE) virus. The license covers the US, Europe, Asia, Latin America, and other countries.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis makes $84mm JE vaccine deal with Intercell; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice